DANONE (BSN.DE) Fundamental Analysis & Valuation
FRA:BSN • FR0000120644
Current stock price
66.78 EUR
+0.66 (+1%)
Last:
This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BSN.DE Profitability Analysis
1.1 Basic Checks
- BSN had positive earnings in the past year.
- BSN had a positive operating cash flow in the past year.
- In the past 5 years BSN has always been profitable.
- In the past 5 years BSN always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 4.03%, BSN is in line with its industry, outperforming 57.63% of the companies in the same industry.
- With a decent Return On Equity value of 10.73%, BSN is doing good in the industry, outperforming 61.02% of the companies in the same industry.
- With a decent Return On Invested Capital value of 7.75%, BSN is doing good in the industry, outperforming 66.10% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.16%.
- The last Return On Invested Capital (7.75%) for BSN is above the 3 year average (7.51%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROIC | 7.75% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
1.3 Margins
- The Profit Margin of BSN (6.66%) is better than 62.71% of its industry peers.
- In the last couple of years the Profit Margin of BSN has declined.
- Looking at the Operating Margin, with a value of 13.43%, BSN belongs to the top of the industry, outperforming 84.75% of the companies in the same industry.
- In the last couple of years the Operating Margin of BSN has remained more or less at the same level.
- BSN has a Gross Margin of 50.62%. This is amongst the best in the industry. BSN outperforms 83.05% of its industry peers.
- In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% |
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
2. BSN.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
- Compared to 1 year ago, BSN has less shares outstanding
- Compared to 5 years ago, BSN has less shares outstanding
- Compared to 1 year ago, BSN has a worse debt to assets ratio.
2.2 Solvency
- BSN has an Altman-Z score of 2.34. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
- BSN has a better Altman-Z score (2.34) than 62.71% of its industry peers.
- BSN has a debt to FCF ratio of 5.29. This is a neutral value as BSN would need 5.29 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 5.29, BSN is doing good in the industry, outperforming 71.19% of the companies in the same industry.
- A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
- BSN has a Debt to Equity ratio of 0.73. This is in the lower half of the industry: BSN underperforms 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Altman-Z | 2.34 |
ROIC/WACC1.23
WACC6.32%
2.3 Liquidity
- A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
- The Current ratio of BSN (0.90) is worse than 81.36% of its industry peers.
- BSN has a Quick Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
- BSN has a Quick ratio of 0.75. This is in the lower half of the industry: BSN underperforms 62.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 |
3. BSN.DE Growth Analysis
3.1 Past
- BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
- BSN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.61% yearly.
- BSN shows a decrease in Revenue. In the last year, the revenue decreased by -0.34%.
- The Revenue has been growing slightly by 2.93% on average over the past years.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
3.2 Future
- Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 7.92% on average per year.
- Based on estimates for the next years, BSN will show a small growth in Revenue. The Revenue will grow by 3.94% on average per year.
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.92%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y3.94%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BSN.DE Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 17.57 indicates a rather expensive valuation of BSN.
- Compared to the rest of the industry, the Price/Earnings ratio of BSN is on the same level as its industry peers.
- BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.77.
- The Price/Forward Earnings ratio is 16.49, which indicates a correct valuation of BSN.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BSN is on the same level as its industry peers.
- BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.75, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.57 | ||
| Fwd PE | 16.49 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSN.
- Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than 66.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.7 | ||
| EV/EBITDA | 9.11 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.68
PEG (5Y)6.72
EPS Next 2Y6.99%
EPS Next 3Y7.19%
5. BSN.DE Dividend Analysis
5.1 Amount
- BSN has a Yearly Dividend Yield of 3.30%.
- BSN's Dividend Yield is a higher than the industry average which is at 3.07.
- Compared to an average S&P500 Dividend Yield of 1.82, BSN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.3% |
5.2 History
- The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
5.3 Sustainability
- 75.94% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
- The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.94%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
BSN.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:BSN (4/30/2026, 7:00:00 PM)
66.78
+0.66 (+1%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Industry Strength58.78
Industry Growth70.67
Earnings (Last)04-22 2026-04-22/bmo
Earnings (Next)07-28 2026-07-28
Inst Owners55.19%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap45.50B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target81.39 (21.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.3% |
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.76%
PT rev (3m)0.37%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-2.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.57 | ||
| Fwd PE | 16.49 | ||
| P/S | 1.67 | ||
| P/FCF | 16.7 | ||
| P/OCF | 12.04 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.11 |
EPS(TTM)3.8
EY5.69%
EPS(NY)4.05
Fwd EY6.06%
FCF(TTM)4
FCFY5.99%
OCF(TTM)5.55
OCFY8.31%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.68
PEG (5Y)6.72
Graham Number46.0744 (-31.01%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.03% | ||
| ROE | 10.73% | ||
| ROCE | 12.04% | ||
| ROIC | 7.75% | ||
| ROICexc | 9.68% | ||
| ROICexgc | 76.66% | ||
| OM | 13.43% | ||
| PM (TTM) | 6.66% | ||
| GM | 50.62% | ||
| FCFM | 9.99% |
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 5.29 | ||
| Debt/EBITDA | 2.46 | ||
| Cap/Depr | 77.86% | ||
| Cap/Sales | 3.87% | ||
| Interest Coverage | 21.06 | ||
| Cash Conversion | 75.3% | ||
| Profit Quality | 150.06% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | 2.34 |
F-Score7
WACC6.32%
ROIC/WACC1.23
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.92%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.65%
Revenue Next 2Y3.35%
Revenue Next 3Y3.59%
Revenue Next 5Y3.94%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.46%
EBIT Next 3Y14.84%
EBIT Next 5Y11.04%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%
DANONE / BSN.DE Fundamental Analysis FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for DANONE?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the financial health of DANONE (BSN.DE) stock?
The financial health rating of DANONE (BSN.DE) is 3 / 10.
Can you provide the dividend sustainability for BSN stock?
The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.